University of Miami's 2nd Biennial Miami Leukemia Symposium

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
Avatar

2020 Update on Ph- MPN: What Are the Potential Benefits and Limitations to JAKi? Which Alternative Pathogenetic Mechanisms Can Improve Therapeutic Benefit?

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Olatoyosi Odenike
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Olatoyosi Odenike
156 views
October 23, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
CML and MPNs: Final Frontiers and New Breakthroughs
21:24
University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on Atypical CML, CMML & CNL: Is There Clinical Benef…

Feat. J. Tyner
26:24
University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on CML: What Strategies Can Help Overcome Multi-TKI Resi…

Feat. J. Cortés
25:18
University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on Ph- MPN: What Are the Potential Benefits and Limitati…

Feat. O. Odenike
21:19
University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on BPDCN: Efficacy Analysis of Available Standard Therap…

Feat. N. Pemmaraju